Probatebeta
Target

ADRB1

Beta-1 adrenergic receptor

As of the edition of 20 October 2026, ADRB1 (beta-1 adrenergic receptor, UniProt P08588) has 42 drugs tested at it and 50 companies on the list, 1 on route A and 13 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P08588
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
At a membrane
Solved structures
7
Disease areas
Heart and blood vessels; Nervous system; Eye; Lungs and airways; Infections; Urinary and reproductive; Pregnancy and women's health; Nutrition and metabolism
Registered trials of its drugs
1,267

Drugs at this target

StatusCount
Marketed34
Active1
Went quiet1
Stopped2
Withdrawn from market3
Status not established1
Total42
DrugStatusFurthest phaseUS protection
EpinephrineMarketedPhase 4none listed
NorepinephrineMarketedPhase 4none listed
MetoprololMarketedPhase 4none listed
CarvedilolMarketedPhase 4none listed
TimololMarketedPhase 4none listed
NebivololMarketedPhase 4none listed
BisoprololMarketedPhase 4none listed
EsmololMarketedPhase 4none listed
AtenololMarketedPhase 4none listed
EphedrineMarketedPhase 4none listed
DobutamineMarketedPhase 4none listed
LabetalolMarketedPhase 4none listed

12 of 42 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A1
Route B13
Engaged9
Undetermined27
Total on the list50
Three companies on route A or B, with the route only
CompanyRoute
Eli LillyRoute B
PfizerRoute B
Ono PharmaceuticalRoute B

The other 47 companies at ADRB1

In the product

50 companies in all; 47 are not named here, and no score is.

See the 50 companies at ADRB1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at ADRB1

Other targets in heart and blood vessels

Companies holding approvals at ADRB1